Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Abatacept for prevention of acute GVHD

Kirk Schultz • 15 Mar 2021
EBMT 2021
Abatacept

Abatacept is a selective inhibitor of T cell costimulation. Kirk Schultz, MD, British Columbia Children’s Hospital, Vancouver, Canada, discusses the use of abatacept for the treatment of acute graft-versus-host disease (GvHD), a major cause of death following unrelated-donor (URD) hematopoietic cell transplant (HCT). This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Kirk Schultz

1:07
Identifying operational tolerance pathways after SCT & cGvHD immune profiles with machine learning
Kirk Schultz • 23 Apr 2023
2:25
GvHD biomarker discovery and validation
Kirk Schultz • 15 Mar 2021
0:46
Tackling GvHD together
Kirk Schultz • 15 Mar 2021
The content of VJHemOnc is intended for healthcare professionals